Common use of Submitting Investigator Clause in Contracts

Submitting Investigator. An investigator who submitted a genomic dataset to an NIH designated data repository (e.g., dbGaP). Study specific DUC addendum phs000812 : Characterizing Genetic Susceptibility to Breast and Prostate Cancer - BPC3 Public Posting of Genomic Summary Results - Allowed. NIH Data Access Committee (DAC) : NCI DAC Important Contacts : XXXXXX@xxxx.xxx.xxx; XXX@xxxx.xxx.xxx In the event of a data management incident, within 24 hours, please contact emails above. The Breast and Prostate Cancer Cohort Consortium (BPC3) genome-wide association studies of advanced prostate cancer and estrogen-receptor negative breast cancer was supported by the National Cancer Institute under cooperative agreements U01-CA98233, U01-CA98710, U01-CA98216, and U01-CA98758 and the Intramural Research Program of the National Cancer Institute, Division of Cancer Epidemiology and Genetics. The BPC3 investigators request that publications resulting from the use of these data cite their original publications, as relevant: Xxxxxxxxxx FR, Xxxxxx SI, Xxxxxx A, Xxxxxx KB, Xxxx Z, Xxxxxxxxx S, Xxxxxxx XX, Xxxx C, Xxxxxx AM, Xxxxxx XX, Xxxxx DO, Xxxxx XX, Xxxxxx XX, Xxxxx G, Xxxxxx XX, Xxxx DE, Xxxxx FC, Xxxxxxx XX, Xxxx K, Xx Xxxxx AA, Xxxx-Xxxxx Z, Xxx X, Xxxxxx G, Xxxxxxxx H, Xxxxxx XX, Xxxxxxxx R, Xxxxxxx F, Xx J, Xxxxx NE, Xxxxxxxx XX, Xxxxxxxxxx A, Boeing H, Xxxxx-xx-Xxxxxxxx HB, Xxxxxxxx XX, Xxxxx XX, Xxxxxxxx CA, Xxxxxxx XX, Xxxxxxxxxxx EL, Xxxxxxxxx M, Xx Xxxxxxxx L, Xx J, Xxxxx S, Xxxxxxx P, Xxxxxxxx XX, Xxxxxxxxxx A, Xxxxxx P, Xxxxxxx J, Xxxxx U, Xxxxxxxxx XX, Xxxxxx M, Xxxx XX, Xxxxxxx LN, Xxxxxxxxx BE, Xxxxxxx D, Xxxxx XX, Xxxxxxxxx XX, Xxxxxx E, Xxxxxx XX, Xxxxxxx XX, Xxxxxx CA, Xxxxx P. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet. 2011 Oct 1;20(19):3867-75. Acknowledgement Statement : Siddiq A, Xxxxx XX, Xxxx XX, Xxxxxxxxx S, Xxxxxx D, Xxxxxxxx XX, Xxxxxxxxxxx K, Xxxxx DO, Xxxxxxxx L, Xxxx XX, Xxxxxxxxx XX, Xxxxxxxxx K, Xxxxxx P, Xxxxxxxx C; Australian Breast Cancer Tissue Bank Investigators, Xxxxxxxxx L, Xxxxxxx EV, Xxxxxxxx XX, Xxxx XX, Xxxxxxxxx L, Xxxxxxxxx C, Xxxxxx H, Xxxxxxx L, Xxx QM, Xxxxxx XX, Xxxx SS, Xxxxx D, Xxxxxxxxx XX, Xxxxxxx DI, Xxxxx-Xxxxxx X, Xxxx C, Xxxxxx-Xxxxxxxx F, Xxx A, Xxxxx SS, Xxxxx K, Xxxxxx XX, Xxxxxx XX, Xxxxx XX, Xxxxxxx AM, Xxxxxx L, Xxxxx XX, Xxxxxxxx PA; Familial Breast Cancer Study, Xxxxxxxxx XX, Xxxxxxxx L, Xxxxxxxx XX, Xxxxxxxx O, Xxxxxx-Xxxxx D, Xxxxxx XX; GENICA Consortium, Xxxxx XX, Xxxxxxxxx-Xxx JL, Xxxxx XX, xxx Xxxx CH, Xxxxxx AK, Xxxxxx N, Xxxxx D, Xxxx P, Xxxxxxxxx XX, Xxxxxxxx A, Xxxx R, Xxxxx J, Xxxxxx XX, Xxxxxx XX, Xx XX, Xxxxxxxx S, Xxxxxx XX, Xxxxxxx A, Xxxxxx C, Xxxxxx KB, Xxxx EM, Xxxxxxxxxxx C, Xxxxx R, Xxxxxxx LN, Xxxxxxx GA, Xxxxxxx M, Xx Xxxxxxxx L, Xxx AM, Xxx IM, Xxxxxxx T, Xxxxxxxx P, Xxx J, Xxxx E, Xxxxxxx E, Xxxxxx XX, XxXxxx CA, Xxxxxxx-Xxxxxxxx H, Xxxxxx A, Xxxxx P, Xxxxxx XX, Xxxxxxxxxx XX, Xxxxxx-Myhsok B, Xxxxxxx S, Xxxxxx XX, Xxxxxxx C, Xxxxxxx K, Xxxxx D, Park DJ, Xxxxxx XX, Xxxxxx H, Xxxx J, Xxxxxxx P, Xxxxxx N, Xxxxxxxxxxx F, Xxxxxxx XX, Xxxxxxxxxx XX, Xxxxxx S, Xxxxxxx MC, Xxxxxxx XX, Xxxx HP, Press MF, Xxxx E, Xxxxxx E, Xxxxxx PM, Xxxxxxxxxx FR, Xxxxxx G, Xxx Xxxxxx Xxxxx I, Xxxxx J, Xxxx M, Xxxxxx XX, Xxxx XX, Xxxxxx XX, Xxxxxxxx C, Xxxxxxxxxxxx AG, Waisfisz Q, Xxxx X, Xxxx Z, Xxxxxx J, Xxxxxx-Xxxxxxxxx R, Xxxxxxx XX, Xxx Xxx Xxxx D, Xxxxx W, Xxxxxxx XX, Xxx E, Xxxxxxxxxx H, Xxxxxx XX, Xxxxxx XX, Xxxxxxxxx BE, Xxxxxxx XX, Xxxxxx-Xxxxxx M, Xxxxx P, Xxxxxx CA, Xxxxxx XX. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet. 2012 Dec 15;21(24):5373-84. Name : General Research Use (MDS) Consent Group # : 1 Abbreviation : GRU-MDS Data Use Limitation : Use of the data is limited only by the terms of the model Data Use Certification. Use of the data includes methods development research (e.g., development of software or algorithms). Name : Health/Medical/Biomedical (PUB, MDS) Consent Group # : 2 Abbreviation : HMB-PUB-MDS Data Use Limitation : Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry. Requestor agrees to make results of studies using the data available to the larger scientific community. Use of the data includes methods development research (e.g., development of software or algorithms). Name : Disease-Specific (Breast, Ovarian, or Endometrial Disease, MDS) Consent Group # : 3 Abbreviation : DS-BOED-MDS Data Use Limitation : Use of the data must be related to Breast, Ovarian, or Endometrial Disease. Use of the data includes methods development research (e.g., development of software or algorithms). Name : Cancer in all age groups, other disease in adults only and methods Consent Group # : 4 Abbreviation : CADM The informed consent document signed by the study participants allows use of these data by investigators for Data Use Limitation : discovery and hypothesis generation in the investigation of the genetic contributions to cancer in all age groups

Submitting Investigator. An investigator who submitted a genomic dataset to an NIH designated data repository (e.g., dbGaP). Study specific DUC addendum phs000812 phs000734 : Characterizing Genetic Susceptibility to Breast and Prostate Cancer - BPC3 A Genome-wide Association Study (GWAS) of Risk for Osteosarcoma Public Posting of Genomic Summary Results - Not Allowed. NIH Data Access Committee (DAC) : NCI DAC Important Contacts : XXXXXX@xxxx.xxx.xxx; XXX@xxxx.xxx.xxx In the event of a data management incident, within 24 hours, please contact emails above. The Breast and Prostate Cancer Cohort Consortium (BPC3) genomeWhen referencing the GWAS of Risk for Osteosarcoma Dataset(s), please cite the following publication: Xxxxxx XX, Xxxxxxxxx L, Xxxx Z, Xxxxxxx-wide association studies of advanced prostate cancer and estrogenXxxxxx XX, Xxxxxxx R, Xxxxxx C, Xxxxxxxx AM, Xxxxxxxxx R, Xxxxxxxx IL, Xxxxxx XX, Xxxxxx N, Xxxxxx-receptor negative breast cancer was supported by the National Cancer Institute under cooperative agreements U01-CA98233Xxxxxx A, U01-CA98710Sierrasesúmaga L, U01-CA98216Xxxxxxx F, and U01-CA98758 and the Intramural Research Program of the National Cancer InstituteXxxxxx N, Division of Cancer Epidemiology and Genetics. The BPC3 investigators request that publications resulting from the use of these data cite their original publicationsXxxxx IE, as relevantSari N, Xxxxx M, Acknowledgement Statement : Hattinger C, Xxxxx P, Xxxxxxx XX, Xxxxxxxxxx FRDA, Xxxxxx N, xx Xxxxxx SR, Xxxxxxxx AS, Xxxxx XX, Xxxxx D, Xxxxxx XX, Xxxxxxxx C, Xxxxxxx XX, Xxxxxx K, Xxxxx XX, Xxxxxx SI, Xxxxxx A, Xxxxxx KB, Xxxx Z, Xxxxxxxxx S, Xxxxxxx XX, Xxxx C, Xxxxxx AM, Xxxxxx XX, Xxxxx DO, Xxxxx XX, Xxxxxx XX, Xxxxx G, Xxxxxx XX, Xxxx DE, Xxxxx FC, Xxxxxxx XX, Xxxx K, Xx Xxxxx AA, Xxxx-Xxxxx Z, Xxx X, Xxxxxx GMP, Xxxxxxxx H, Xxxxxx XX, Xxxxxxxx R, Xxxxxxx F, Xx J, Xxxxx NE, Xxxxxxxx XX, Xxxxxxxxxx A, Boeing H, Xxxxx-xx-Xxxxxxxx HB, Xxxxxxxx XX, Xxxxx XX, Xxxxxxxx CA, Xxxxxxx XX, Xxxxxxxxxxx EL, Xxxxxxxxx M, Xx Xxxxxxxx L, Xx J, Xxxxx S, Xxxxxxx P, Xxxxxxxx XX, Xxxxxxxxxx A, Xxxxxx P, Xxxxxxx J, Xxxxx U, Xxxxxxxxx XX, Xxxxxx M, Xxxx XX, Xxxxxxx LN, Xxxxxxxxx BE, Xxxxxxx DN, Xxxxx XXMT, Xxxxxxxxx XX, Xxxxxx E, Xxxxxx XX, Xxxxxxx XX, Xxxxxx CA, Xxxxx P. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet. 2011 Oct 1;20(19):3867-75. Acknowledgement Statement : Siddiq A, Xxxxx XX, Xxxx XX, Xxxxxxxxx S, Xxxxxx D, Xxxxxxxx XX, Xxxxxxxxxxx K, Xxxxx DO, Xxxxxxxx L, Xxxx XX, Xxxxxxxxx XX, Xxxxxxxxx K, Xxxxxx P, Xxxxxxxx C; Australian Breast Cancer Tissue Bank Investigators, Xxxxxxxxx L, Xxxxxxx EV, Xxxxxxxx XX, Xxxx XX, Xxxxxxxxx L, Xxxxxxxxx C, Xxxxxx H, Xxxxxxx L, Xxx QM, Xxxxxx XX, Xxxx SS, Xxxxx D, Xxxxxxxxx XX, Xxxxxxx DI, Xxxxx-Xxxxxx X, Xxxx C, Xxxxxx-Xxxxxxxx F, Xxx A, Xxxxx SS, Xxxxx K, Xxxxxx XX, Xxxxxx XX, Xxxxx XX, Xxxxxxx AM, Xxxxxx L, Xxxxx XX, Xxxxxxxx PA; Familial Breast Cancer Study, Xxxxxxxxx XX, Xxxxxxxx L, Xxxxxxxx XX, Xxxxxxxx O, Xxxxxx-Xxxxx D, Xxxxxx XX; GENICA Consortium, Xxxxx XX, Xxxxxxxxx-Xxx JL, Xxxxx XX, xxx Xxxx CH, Xxxxxx AK, Xxxxxx N, Xxxxx D, Xxxx P, Xxxxxxxxx XX, Xxxxxxxx A, Xxxx R, Xxxxx J, Xxxxxx XX, Xxxxxx XX, Xx XX, Xxxxxxxx S, Xxxxxx XX, Xxxxxxx A, Xxxxxx C, Xxxxxx KB, Xxxx EM, Xxxxxxxxxxx C, Xxxxx R, Xxxxxxx LN, Xxxxxxx GA, Xxxxxxx M, Xx Xxxxxxxx L, Xxx AM, Xxx IM, Xxxxxxx T, Xxxxxxxx P, Xxx J, Xxxx E, Xxxxxxx E, Xxxxxx XX, XxXxxx CA, Xxxxxxx-Xxxxxxxx H, Xxxxxx A, Xxxxx P, Xxxxxx XX, Xxxxxxxxxx XXXxxxxx N, Xxxxxx-Myhsok BKogevinas M, Xxxxxxx Xxxxxxxxx S, Xxxxxx R, Xxxxxx L, Xxxxxxxx XX Xx, Xxxxxx M, Xxxxxx XX, Xxxxxxx C, Xxxxxxx K, Xxxxx D, Park DJ, Xxxxxx XX, Xxxxxx H, Xxxx J, Xxxxxxx P, Xxxxxx N, Xxxxxxxxxxx F, Xxxxxxx XX, Xxxxxxxxxx XX, Xxxxxx S, Xxxxxxx MC, Xxxxxxx XX, Xxxx HP, Press MF, Xxxx E, Xxxxxx E, Xxxxxx PM, Xxxxxxxxxx FR, Xxxxxx G, Xxx Xxxxxx Xxxxx I, Xxxxx J, Xxxx M, Xxxxxx XX, Xxxx XX, Xxxxxx XX, Xxxxxxxx C, Xxxxxxxxxxxx AG, Waisfisz Q, Xxxx X, Xxxx Z, Xxxxxx J, Xxxxxx-Xxxxxxxxx R, Xxxxxxx XX, Xxx Xxx Xxxx D, Xxxxx W, Xxxxxxx XX, Xxx E, Xxxxxxxxxx H, Xxxxxx XX, Xxxxxx XX, Xxxxxxxxx BE, Xxxxxxx XX, Xxxxxx-Xxxxxx M, Xxxxx P, Xxxxxx CA, Xxxxxx XX. A meta-analysis of genomeGenome-wide association studies of breast cancer study identifies two novel susceptibility loci at 6q14 and 20q11for osteosarcoma. Hum Mol Nat Genet. 2012 Dec 15;21(24):53732013 Jul;45(7):799-84803. Name : General Research Use (MDS) Consent Group # : 1 Abbreviation : GRU-MDS Data Use Limitation : Use of the data is limited only by the terms of the model Data Use Certification. Use of the data includes methods development research (e.g., development of software or algorithms). Name : Health/Medical/Biomedical (PUB, MDS) Consent Group # : 2 Abbreviation : HMB-PUB-MDS Data Use Limitation : Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry. Requestor agrees to make results of studies using the data available to the larger scientific community. Use of the data includes methods development research (e.g., development of software or algorithms). Name : Disease-Specific (Breast, Ovarian, or Endometrial Disease, MDS) Consent Group # : 3 Abbreviation : DS-BOED-MDS Data Use Limitation : Use of the data must be related to Breast, Ovarian, or Endometrial Disease. Use of the data includes methods development research (e.g., development of software or algorithms). Name : Cancer in all age groups, other disease in adults only and methods Consent Group # : 4 Abbreviation : CADM The informed consent document signed by the study participants allows use of these data by investigators for Data Use Limitation : discovery and hypothesis generation in the investigation of the genetic contributions to cancer in all age groups

Submitting Investigator. An investigator who submitted a genomic dataset to an NIH designated data repository (e.g., dbGaP). Study specific DUC addendum phs000812 phs000689 : Characterizing Genetic Susceptibility to Breast and Prostate Cancer - BPC3 Genomic Analysis of Peripheral T-Cell Lymphomas Public Posting of Genomic Summary Results - Allowed. NIH Data Access Committee (DAC) : NCI DAC Important Contacts : XXXXXX@xxxx.xxx.xxx; XXX@xxxx.xxx.xxx In the event of a data management incident, within 24 hours, please contact emails above. The Breast and Prostate Cancer Cohort Consortium (BPC3) genome-wide association studies of advanced prostate cancer and estrogen-receptor negative breast cancer was supported by the National Cancer Institute under cooperative agreements U01-CA98233, U01-CA98710, U01-CA98216, and U01-CA98758 and the Intramural Research Program of the National Cancer Institute, Division of Cancer Epidemiology and Genetics. The BPC3 investigators request that publications resulting from the use of these data cite their original publications, as relevant: Xxxxxxxxxx FRXxxxxx Xxxxxxxx, Xxxxxx SIXxxxxxxx, Xxxxxxx Xxxxxxxxxx, Xx-Xxxx Xxx, Xxxxxxx Xxxxxx-Xxxxxxxxxx, Xxxxxxx Xxxxx-Xxxxxx, Xxxxxxx Xxxxxxxxx, Xxxxxxxxx Xxxxx, Xxxxxxxxx Xxxxxxxxxx, X. Xxxxx Xxxxx, Xxxxxx A, Xxxxxx KB, Xxxx Z, Xxxxxxxxx SXxxxx, Xxxxxxx XX, Xxxx C, Xxxxxx AM, Xxxxxx XX, Xxxxx DO, Xxxxx XX, Xxxxxx XX, Xxxxx G, Xxxxxx XX, Xxxx DE, Xxxxx FC, Xxxxxxx XX, Xxxx K, Xx Xxxxx AA, Xxxx-Xxxxx Z, Xxx X, Xxxxxx G, Xxxxxxxx H, Xxxxxx XX, Xxxxxxxx R, Xxxxxxx F, Xx J, Xxxxx NE, Xxxxxxxx XX, Xxxxxxxxxx A, Boeing H, Xxxxx-xx-Xxxxxxxx HB, Xxxxxxxx XX, Xxxxx XX, Xxxxxxxx CA, Xxxxxxx XX, Xxxxxxxxxxx EL, Xxxxxxxxx M, Xx Xxxxxxxx L, Xx J, Xxxxx S, Xxxxxxx P, Xxxxxxxx XX, Xxxxxxxxxx A, Xxxxxx P, Xxxxxxx J, Xxxxx U, Xxxxxxxxx XX, Xxxxxx M, Xxxx XX, Xxxxxxx LN, Xxxxxxxxx BE, Xxxxxxx D, Xxxxx XX, Xxxxxxxxx XX, Xxxxxx E, Xxxxxx XX, Xxxxxxx XX, Xxxxxx CA, Xxxxx P. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet. 2011 Oct 1;20(19):3867-75. Acknowledgement Statement : Siddiq AX. Xxxxxx, Xxxxxx Xxxxxxx, Xxxxxxxx Xxxxxx, Xxxxxxxxx Xxxxxxx, Xxxxxx Xxxxxx, Xxxxxx Xxxxx Xxxxx, Xxxxx XXXxxxx, Xxxxxxx Xxxxxxx, Xxxx XXXxxxxxx and Xxxxxx Xxxxxxxx. Recurrent epigenetic, Xxxxxxxxx SRHOA, Xxxxxx D, Xxxxxxxx XX, Xxxxxxxxxxx K, Xxxxx DO, Xxxxxxxx L, Xxxx XX, Xxxxxxxxx XX, Xxxxxxxxx K, Xxxxxx P, Xxxxxxxx C; Australian Breast Cancer Tissue Bank Investigators, Xxxxxxxxx L, Xxxxxxx EV, Xxxxxxxx XX, Xxxx XX, Xxxxxxxxx L, Xxxxxxxxx C, Xxxxxx H, Xxxxxxx L, Xxx QM, Xxxxxx XX, Xxxx SS, Xxxxx D, Xxxxxxxxx XX, Xxxxxxx DI, XxxxxFYN kinase and immune surveillance escape mutations in peripheral T-Xxxxxx X, Xxxx C, Xxxxxx-Xxxxxxxx F, Xxx A, Xxxxx SS, Xxxxx K, Xxxxxx XX, Xxxxxx XX, Xxxxx XX, Xxxxxxx AM, Xxxxxx L, Xxxxx XX, Xxxxxxxx PA; Familial Breast Cancer Study, Xxxxxxxxx XX, Xxxxxxxx L, Xxxxxxxx XX, Xxxxxxxx O, Xxxxxx-Xxxxx D, Xxxxxx XX; GENICA Consortium, Xxxxx XX, Xxxxxxxxx-Xxx JL, Xxxxx XX, xxx Xxxx CH, Xxxxxx AK, Xxxxxx N, Xxxxx D, Xxxx P, Xxxxxxxxx XX, Xxxxxxxx A, Xxxx R, Xxxxx J, Xxxxxx XX, Xxxxxx XX, Xx XX, Xxxxxxxx S, Xxxxxx XX, Xxxxxxx A, Xxxxxx C, Xxxxxx KB, Xxxx EM, Xxxxxxxxxxx C, Xxxxx R, Xxxxxxx LN, Xxxxxxx GA, Xxxxxxx M, Xx Xxxxxxxx L, Xxx AM, Xxx IM, Xxxxxxx T, Xxxxxxxx P, Xxx J, Xxxx E, Xxxxxxx E, Xxxxxx XX, XxXxxx CA, Xxxxxxx-Xxxxxxxx H, Xxxxxx A, Xxxxx P, Xxxxxx XX, Xxxxxxxxxx XX, Xxxxxx-Myhsok B, Xxxxxxx S, Xxxxxx XX, Xxxxxxx C, Xxxxxxx K, Xxxxx D, Park DJ, Xxxxxx XX, Xxxxxx H, Xxxx J, Xxxxxxx P, Xxxxxx N, Xxxxxxxxxxx F, Xxxxxxx XX, Xxxxxxxxxx XX, Xxxxxx S, Xxxxxxx MC, Xxxxxxx XX, Xxxx HP, Press MF, Xxxx E, Xxxxxx E, Xxxxxx PM, Xxxxxxxxxx FR, Xxxxxx G, Xxx Xxxxxx Xxxxx I, Xxxxx J, Xxxx M, Xxxxxx XX, Xxxx XX, Xxxxxx XX, Xxxxxxxx C, Xxxxxxxxxxxx AG, Waisfisz Q, Xxxx X, Xxxx Z, Xxxxxx J, Xxxxxx-Xxxxxxxxx R, Xxxxxxx XX, Xxx Xxx Xxxx D, Xxxxx W, Xxxxxxx XX, Xxx E, Xxxxxxxxxx H, Xxxxxx XX, Xxxxxx XX, Xxxxxxxxx BE, Xxxxxxx XX, Xxxxxx-Xxxxxx M, Xxxxx P, Xxxxxx CA, Xxxxxx XXcell lymphomas. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet. 2012 Dec 15;21(24):5373-84. Nature Genetics (under review) Name : General Research Use Disease-Specific (Cancer, PUB, MDS) Consent Group # : 1 Abbreviation : GRUDS-MDS Data Use Limitation : Use of the data is limited only by the terms of the model Data Use Certification. Use of the data includes methods development research (e.g., development of software or algorithms). Name : Health/Medical/Biomedical (PUB, MDS) Consent Group # : 2 Abbreviation : HMBCA-PUB-MDS Data Use Limitation : Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry. Requestor agrees to make results of studies using the data available to the larger scientific community. Use of the data includes methods development research (e.g., development of software or algorithms). Name : Disease-Specific (Breast, Ovarian, or Endometrial Disease, MDS) Consent Group # : 3 Abbreviation : DS-BOED-MDS Data Use Limitation : Use of the data must be related to Breast, Ovarian, or Endometrial Disease. Use of the data includes methods development research (e.g., development of software or algorithms). Name : Cancer in all age groups, other disease in adults only and methods Consent Group # : 4 Abbreviation : CADM The informed consent document signed by the study participants allows use of these data by investigators for Data Use Limitation : discovery and hypothesis generation in the investigation of the genetic contributions to cancer in all age groupsCancer.

Submitting Investigator. An investigator who submitted a genomic dataset to an NIH designated data repository (e.g., dbGaP). Study specific DUC addendum phs000812 phs001059 : Characterizing Genetic Susceptibility to Breast and Prostate Cancer - BPC3 Maternal Plasma Folate impacts Differential DNA Methylation in an Epigenome-wide Meta-Analysis of Newborns Public Posting of Genomic Summary Results - Not Allowed. NIH Data Access Committee (DAC) : NCI NIEHS DAC Important Contacts : XXXXXX@xxxx.xxx.xxxxxxxxxx0@xxxxx.xxx.xxx; XXX@xxxx.xxx.xxx In the event of a data management incident, within 24 hours, please contact emails above. The Breast and Prostate Cancer Cohort Consortium (BPC3) genome-wide association studies of advanced prostate cancer and estrogen-receptor negative breast cancer was supported by the National Cancer Institute under cooperative agreements U01-CA98233IC Specific Access Term : None Acknowledgement Statement : We acknowledge Xxxxxxx, U01-CA98710BR, U01-CA98216den Xxxxxx, XX, Xxxxx, JF, Xxxxxx, X Xxxxxxxx, S, Xxxxxxx, E, Xxxxxxxx, H, xxx Xxxxx, XX, Xxxxxxxxxxxx, AG, Xxxxxx, A, Xxxxxx, XX, Xxxxx, XX, Xxxxxx, M, Xxxxxxxxxx, XX, Xxxxxxxx, EAP, Xxxxxx, XX, Xxxxxxx, SE, Xxxxxxx, O, Xxxxxx, PM, Xxxxxx, O, Xxxxxxx, A, xx Xxxxxxx, J, Xx, MC, Xxxx, T, Xxxxxxx, SD, Jaddoe, VWV, Xxxxxx, W, Duijts, L, and U01-CA98758 and London, SJ (PI); the Intramural Research Program of the NIH, National Cancer InstituteInstitute of Environmental Health Sciences (Z01-ES-49019), Division the NIH Office of Cancer Epidemiology Dietary Supplements, the Norwegian Ministry of Health and Geneticsthe Ministry of Education and Research, NIH/NIEHS (contract no. The BPC3 investigators request that publications resulting from NO1-ES-75558), NIH/NINDS (grant no. 1 U01 NS 047537-01, the use of these data cite their original publicationsNorwegian Research Council/FUGE (grant no. 151918/S10), as relevant: Xxxxxxxxxx FRErasmus Medical Center, Xxxxxx SIRotterdam, Xxxxxx Athe Erasmus University Rotterdam, Xxxxxx KB, Xxxx Z, Xxxxxxxxx S, Xxxxxxx XX, Xxxx C, Xxxxxx AM, Xxxxxx XX, Xxxxx DO, Xxxxx XX, Xxxxxx XX, Xxxxx G, Xxxxxx XX, Xxxx DE, Xxxxx FC, Xxxxxxx XX, Xxxx K, Xx Xxxxx AA, Xxxx-Xxxxx Z, Xxx X, Xxxxxx G, Xxxxxxxx H, Xxxxxx XX, Xxxxxxxx R, Xxxxxxx F, Xx J, Xxxxx NE, Xxxxxxxx XX, Xxxxxxxxxx A, Boeing H, Xxxxx-xx-Xxxxxxxx HB, Xxxxxxxx XX, Xxxxx XX, Xxxxxxxx CA, Xxxxxxx XX, Xxxxxxxxxxx EL, Xxxxxxxxx M, Xx Xxxxxxxx L, Xx J, Xxxxx S, Xxxxxxx P, Xxxxxxxx XX, Xxxxxxxxxx A, Xxxxxx P, Xxxxxxx J, Xxxxx U, Xxxxxxxxx XX, Xxxxxx M, Xxxx XX, Xxxxxxx LN, Xxxxxxxxx BE, Xxxxxxx D, Xxxxx XX, Xxxxxxxxx XX, Xxxxxx E, Xxxxxx XX, Xxxxxxx XX, Xxxxxx CA, Xxxxx P. Genomeand the Netherlands Organization for Health Research and Development. Maternal plasma folate impacts differential DNA methylation in an epigenome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet. 2011 Oct 1;20(19):3867-75. Acknowledgement Statement : Siddiq A, Xxxxx XX, Xxxx XX, Xxxxxxxxx S, Xxxxxx D, Xxxxxxxx XX, Xxxxxxxxxxx K, Xxxxx DO, Xxxxxxxx L, Xxxx XX, Xxxxxxxxx XX, Xxxxxxxxx K, Xxxxxx P, Xxxxxxxx C; Australian Breast Cancer Tissue Bank Investigators, Xxxxxxxxx L, Xxxxxxx EV, Xxxxxxxx XX, Xxxx XX, Xxxxxxxxx L, Xxxxxxxxx C, Xxxxxx H, Xxxxxxx L, Xxx QM, Xxxxxx XX, Xxxx SS, Xxxxx D, Xxxxxxxxx XX, Xxxxxxx DI, Xxxxx-Xxxxxx X, Xxxx C, Xxxxxx-Xxxxxxxx F, Xxx A, Xxxxx SS, Xxxxx K, Xxxxxx XX, Xxxxxx XX, Xxxxx XX, Xxxxxxx AM, Xxxxxx L, Xxxxx XX, Xxxxxxxx PA; Familial Breast Cancer Study, Xxxxxxxxx XX, Xxxxxxxx L, Xxxxxxxx XX, Xxxxxxxx O, Xxxxxx-Xxxxx D, Xxxxxx XX; GENICA Consortium, Xxxxx XX, Xxxxxxxxx-Xxx JL, Xxxxx XX, xxx Xxxx CH, Xxxxxx AK, Xxxxxx N, Xxxxx D, Xxxx P, Xxxxxxxxx XX, Xxxxxxxx A, Xxxx R, Xxxxx J, Xxxxxx XX, Xxxxxx XX, Xx XX, Xxxxxxxx S, Xxxxxx XX, Xxxxxxx A, Xxxxxx C, Xxxxxx KB, Xxxx EM, Xxxxxxxxxxx C, Xxxxx R, Xxxxxxx LN, Xxxxxxx GA, Xxxxxxx M, Xx Xxxxxxxx L, Xxx AM, Xxx IM, Xxxxxxx T, Xxxxxxxx P, Xxx J, Xxxx E, Xxxxxxx E, Xxxxxx XX, XxXxxx CA, Xxxxxxx-Xxxxxxxx H, Xxxxxx A, Xxxxx P, Xxxxxx XX, Xxxxxxxxxx XX, Xxxxxx-Myhsok B, Xxxxxxx S, Xxxxxx XX, Xxxxxxx C, Xxxxxxx K, Xxxxx D, Park DJ, Xxxxxx XX, Xxxxxx H, Xxxx J, Xxxxxxx P, Xxxxxx N, Xxxxxxxxxxx F, Xxxxxxx XX, Xxxxxxxxxx XX, Xxxxxx S, Xxxxxxx MC, Xxxxxxx XX, Xxxx HP, Press MF, Xxxx E, Xxxxxx E, Xxxxxx PM, Xxxxxxxxxx FR, Xxxxxx G, Xxx Xxxxxx Xxxxx I, Xxxxx J, Xxxx M, Xxxxxx XX, Xxxx XX, Xxxxxx XX, Xxxxxxxx C, Xxxxxxxxxxxx AG, Waisfisz Q, Xxxx X, Xxxx Z, Xxxxxx J, Xxxxxx-Xxxxxxxxx R, Xxxxxxx XX, Xxx Xxx Xxxx D, Xxxxx W, Xxxxxxx XX, Xxx E, Xxxxxxxxxx H, Xxxxxx XX, Xxxxxx XX, Xxxxxxxxx BE, Xxxxxxx XX, Xxxxxx-Xxxxxx M, Xxxxx P, Xxxxxx CA, Xxxxxx XX. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11newborns. Hum Mol Genet. 2012 Dec 15;21(24):5373-84Nature Communications, 2016. Name : General Research Use (MDS) Consent Group # : 1 Abbreviation : GRU-MDS Data Use Limitation : Use of the data is limited only by the terms of the model Data Use Certification. Use of the data includes methods development research (e.g., development of software or algorithms). Name : Health/Medical/Biomedical (PUB, MDS) Consent Group # : 2 Abbreviation : HMB-PUB-MDS Data Use Limitation : Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry. Requestor agrees to make results of studies using the data available to the larger scientific community. Use of the data includes methods development research (e.g., development of software or algorithms). Name : Disease-Specific (Breast, Ovarian, or Endometrial Disease, MDS) Consent Group # : 3 Abbreviation : DS-BOED-MDS Data Use Limitation : Use of the data must be related to Breast, Ovarian, or Endometrial Disease. Use of the data includes methods development research (e.g., development of software or algorithms). Name : Cancer in all age groups, other disease in adults only and methods Consent Group # : 4 Abbreviation : CADM The informed consent document signed by the study participants allows use of these data by investigators for Data Use Limitation : discovery and hypothesis generation in the investigation of the genetic contributions to cancer in all age groups